Amid growing concerns regarding the quality of off-patent medications approved for public hospitals, China is set to refine its centralized drug procurement policy. The move aims to bolster confidence in the drugs supplied to its citizens by enhancing quality evaluations and oversight mechanisms.
About the Author
